Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease

Source: Annual Congress 2005 - Inhaler devices: challenges and solutions

Session: Inhaler devices: challenges and solutions
Session type: Thematic Poster Session
Number: 855

Disease area: Airway diseases

Abstract

Tiotropium is a new long-acting anticholinergic bronchodilator, which is recommended as first-line therapy in the management of COPD. It is currently available in the form of a dry powder inhaler (Rotahaler®). We have devloped a new pMDI formulation for Tiotropium. The aim of the study was to compare the time-dependent bronchodilator responses (0-24hrs) of Tiotropium delivered through the two delivery devices in patients with stable COPD. A randomized, double-blind, double-dummy, three-period, placebo-controlled, crossover, single-center study was conducted in 19 patients. Single doses of Tiotropium (18mcg) or placebo were administered on three separate study days with the different devices. FEV₁, FVC and SVC were measured during all study visits at several time points over 24 hrs. Inspiratory Capacity (IC) and Residual Volume (RV) were also measured. Appropriate statistical tests were applied. Results: Tiotropium administered through both pMDI (and spacer) and Rotahaler® showed significantly better mean max. changes in FEV1, FVC, and IC values compared to Placebo. Both the devices showed equivalent bronchodilator response. Conclusion: We have demonstrated for the first time that Tiotropium administered by a pMDI and spacer shows equivalent therapeutic bronchodilator response as that administered by a dry powder inhaler.

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Brashier, B. Trupti, P. Mahadik, P. Gokhale, J. G. Gogtay, S. Salvi (Pune, Mumbai, India). Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator therapeutic response as that administered by the Rotahaler in adults with chronic obstructive pulmonary disease. Eur Respir J 2005; 26: Suppl. 49, 855

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
• ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
• Evidence-based eHealth for COPD